Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tecfidera Stands Out From The Pack Of 2013 Drug Launches

Executive Summary

Biogen Idec’s Tecfidera, on track to generate more than $1 billion in sales its first 12 months on the market, was the exceptional drug launch of 2013, in a year that included few breakout stars.

Advertisement

Related Content

Roche's Ocrevus: A Rare First-Year Blockbuster
With Anoro, GSK Takes A Two-Step Toward Bolstering Respiratory
As Eliquis Sales Lag, Bristol/Pfizer Take Action
Celgene Has A Swift Start For Pomalyst Launch
Biogen Idec Undercuts Gilenya With $55,000 Yearly Price For Tecfidera
Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055844

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel